Skip to main content
SpringerLink
Log in

ALL Therapy: Review of the MD Anderson Program

  • Chapter
Acute Leukemias

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

  • 2559 Accesses

Abstract

Prognosis of adult ALL has improved over the last few decades. Following the lead from the pediatric experience, dose-intense multiagent regimens now achieve remission rates exceeding 80% with 5-year survival probabilities of around 40%. In addition, ALL is more and more recognized as a heterogeneous group of diseases. Definition of subgroups based on cytogenetic-molecular markers has important practical implications including better delineation of prognostic groups, design of risk-adapted therapies, and eventually integration of novel agents into existing therapies that target pathways relevant for ALL pathophysiology. The hyper-CVAD program is one example of a regimen that has been successfully patterned after a previous pediatric regimen and that has developed along advances based on better understanding of ALL biology and availability of new drugs with activity in ALL. This article summarizes the rationale for the development of hyper-CVAD, experience with this regimen in adult ALL, and recent modifications and subtype-specific approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Murphy SB, Bowman WP, Abromowitch M, et al. (1986) Results of treatment of advanced-stage Burkitt’s lymphoma and B cell (sIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol 4:1732–1739

    PubMed  CAS  Google Scholar 

  2. Bagley CM Jr, Bostick FW, DeVita VT Jr (1973) Clinical pharmacology of cyclphosphamide. Cancer Res 33:226–233

    PubMed  Google Scholar 

  3. Iversen OH, Iversen U, Ziegler JL, et al. (1974) Cell kinetics in Burkitt lymphoma. Eur J Cancer 10:155–163

    PubMed  CAS  Google Scholar 

  4. Garcia-Manero G, Kantarjian HM (2000) The hyper-CVAD regimen in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am 6:1381–1396

    Article  Google Scholar 

  5. Childhood ALL Collaborative Group (1996) Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: Overview of 42 trials involving 12000 randomized children. Lancet 347:1783–1788

    Article  Google Scholar 

  6. Dekker AW, van’t Veer MB, Sizoo W, et al. (1997) Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group. J Clin Oncol 15:476–482

    PubMed  CAS  Google Scholar 

  7. Kantarjian HM, O’Brien S, Smith TL, et al. (2000) Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 18:547–561

    PubMed  CAS  Google Scholar 

  8. Kantarjian HM, O’Brien S, Smith T, et al. (1994) Acute lymphocytic leukaemia in the elderly: Characteristics and outcome with the vincristine-adriamycin-dexamethasone (VAD) regimen. Br J Haematol 88:94–100

    PubMed  CAS  Google Scholar 

  9. Todeschini G, Tecchio C, Meneghini V, et al. (1998) Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin. Leukemia 12:144–149

    Article  PubMed  CAS  Google Scholar 

  10. Thomas DA, Cortes J, O’Brien S, et al. (2000) Significance of CD20 positivity in de novo acute lymphocytic leukemia (ALL). Blood 96:109a

    Google Scholar 

  11. Thomas DA, Cortes J, Giles F, et al. (2003) Update of the modified hyper-CVAD regimen in newly diagnosed adult acute lymphocytic leukemia (ALL). Blood 102:880a

    Article  CAS  Google Scholar 

  12. Dombret H, Gabert J, Boiron J-M, et al. (2002) Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia — Results of the prospective multicenter LALA-94 trial. Blood 100:2357–2366

    Article  PubMed  CAS  Google Scholar 

  13. Faderl S, Kantarjian HM, Thomas DA, et al. (2000) Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma 36:263–273

    Article  PubMed  CAS  Google Scholar 

  14. Druker BJ, Sawyers CL, Kantarjian H, et al. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038–1042

    Article  PubMed  CAS  Google Scholar 

  15. Ottmann OG, Druker BJ, Sawyers CL, et al. (2002) A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100:1965–1971

    Article  PubMed  CAS  Google Scholar 

  16. Ottmann OG, Wassmann B, Pfeifer H, et al. (2004) Imatinib given concurrently with induction chemotherapy is superior to imatinib subsequent to induction and consolidation in newly diagnosed Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Blood 104:197a

    Google Scholar 

  17. Towatari M, Yanada M, Usui N, et al. (2004) Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 104:3507–3512

    Article  PubMed  CAS  Google Scholar 

  18. Thomas DA, Faderl S, Cortes J, et al. (2004) Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103:4396–4407

    Article  PubMed  CAS  Google Scholar 

  19. Thomas DA, Faderl S, Cortes J, et al. (2004) Update of the Hyper-CVAD and imatinib mesylate regimen in Philadelphia (Ph) positive acute lymphocytic leukemia (ALL). Blood 104:748a

    Google Scholar 

  20. Gill PS, Meyer PR, Pavlova Z, et al. (1986) B cell acute lymphoblastic leukemia in adults. Clinical, morphological, and immunologic findings. J Clin Oncol 4:737–743

    PubMed  CAS  Google Scholar 

  21. Fenaux P, Bourhuis JH, Ribrag V (2001) Burkitt’s acute lymphocytic leukemia (L3 ALL) in adults. Hematol Oncol Clin North Am 15:37–50

    Article  PubMed  CAS  Google Scholar 

  22. Patte C, Philip T, Rodary C, et al. (1986) Improved survival rate in children with stage III and stage IV B cell non-Hodgkin’s lymphoma and leukemia using multi-agent chemotherapy: Results of a study of 114 children from the French Pediatric Oncology Society. J Clin Oncol 4:1219–1226

    PubMed  CAS  Google Scholar 

  23. Reiter A, Schrappe M, Ludwig W-D, et al. (1992) Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: A report of three consecutive studies of the BFM group. Blood 80:2471–2478

    PubMed  CAS  Google Scholar 

  24. Thomas DA, Cortes J, Faderl S, et al. (2005) Hyper-CVAD and rituximab therapy in HIV-negative Burkitt (BL) or Burkitt-like (BLL) leukemia/lymphoma and mature B-cell acute lymphocytic leukemia (B-ALL). J Clin Oncol 23(16S):567s

    Google Scholar 

  25. Cortes J, Thomas D, Rios A, et al. (2002) Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 94:1492–1499

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

    S. Faderl, D. A. Thomas & Hagop M. Kantarjian

Authors
  1. S. Faderl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. A. Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hagop M. Kantarjian
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Berlin Heidelberg

About this chapter

Cite this chapter

Faderl, S., Thomas, D.A., Kantarjian, H.M. (2008). ALL Therapy: Review of the MD Anderson Program. In: Acute Leukemias. Hematologic Malignancies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-72304-2_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-72304-2_12

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-72302-8

  • Online ISBN: 978-3-540-72304-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation